Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne.
² Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: ben.solomon@petermac.org.

Free article

Editorial

A A Thai et al. Ann Oncol. 2018.

Free article

. 2018 Nov 1;29(11):2160-2162.

doi: 10.1093/annonc/mdy415.

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne.
² Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: ben.solomon@petermac.org.

No abstract available

Comment on

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR. Gadgeel S, et al. Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405. Ann Oncol. 2018. PMID: 30215676 Free PMC article. Clinical Trial.